Response to growth hormone with respect to pubertal status on increased dose in idiopathic growth hormone deficiency: An analysis of Turkish children in the KIGS database (Pfizer International Growth Study)

Basit Öğe Kaydı
dc.contributor.authorDarendeliler F.
dc.contributor.authorBerberoglu M.
dc.contributor.authorÖcal G.
dc.contributor.authorAdiyaman P.
dc.contributor.authorBundak R.
dc.contributor.authorGünöz H.
dc.contributor.authorBaş F.
dc.contributor.authorDarcan Ş.
dc.contributor.authorGökşen D.
dc.contributor.authorArslanoglu I.
dc.contributor.authorYildiz M.
dc.contributor.authorErcan O.
dc.contributor.authorErcan G.
dc.contributor.authorÖzerkan E.
dc.contributor.authorCan Ş.
dc.contributor.authorBöber E.
dc.contributor.authorAdal E.
dc.contributor.authorSarikaya S.
dc.contributor.authorDallar Y.
dc.contributor.authorŞiklar Z.
dc.contributor.authorBircan I.
dc.contributor.authorBideci A.
dc.contributor.authorYüksel B.
dc.contributor.authorBüyükgebiz A.
dc.date.accessioned2019-10-27T00:12:10Z
dc.date.available2019-10-27T00:12:10Z
dc.date.issued2005
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: To compare the growth response to growth hormone (GH) treatment in patients with idiopathic GH deficiency (IGHD) who were prepubertal with the response of those who were pubertal at the onset of GH therapy on an increased GH dose. Patients and methods: Among the Turkish patients enrolled in the Pfizer International Growth Study (KIGS) database with the diagnosis of IGHD, the growth data over 2 years of GH therapy were analyzed longitudinally of 113 (79 M) prepubertal (Group 1) and 44 (33 M) pubertal (Group 2) patients. Pubertal signs were reported to be present initially or to have appeared within 6 months of GH therapy in Group 2. Mean ± SD age at onset of therapy was 8.7 ± 3.5 and 13.5 ± 1.8 years; height SDS -4.2 ± 1.4 and -3.2 ± 1.1 (p <0.05) in Groups 1 and 2, respectively. Mid-parental height (MPH) SDS did not show a significant difference between the two groups (4.5 ± 1.1 vs -1.7 ± 1.1). Results: Delta height SDS over 2 years of therapy was significantly higher in Group 1 (1.1 ± 1.0) than in Group 2 (0.7 ± 0.6) (p <0.05) in spite of a significantly lower dose of GH (14.6 ± 3.3 in Group 1 vs 17.0 ± 3.1 IU/m2/week in Group 2, p <0.05). Ht - MPH SDS showed an increase from -2.4 ± 1.7 to -1.4 ± 1.5 in Group 1 and from -1.5 ± 1.5 to -0.8 ± 1.3 in Group 2. Overall delta height SDS showed negative correlations with age (r = -0.32), height SDS (r = -0.41) and height - MPH SDS (r = -0.40) at onset of therapy (p <0.001). Conclusions: These data show that in IGHD the slight increase (15-20%) in the dose of GH during puberty was not adequate to maintain height velocity at the same magnitude as in prepuberty, and thus was not cost effective. © Freund Publishing House Ltd., London.en_US
dc.identifier.doi10.1515/JPEM.2005.18.10.949en_US
dc.identifier.endpage954en_US
dc.identifier.issn0334-018X
dc.identifier.issue10en_US
dc.identifier.pmid16355808en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage949en_US
dc.identifier.urihttps://doi.org/10.1515/JPEM.2005.18.10.949
dc.identifier.urihttps://hdl.handle.net/11454/22292
dc.identifier.volume18en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherFreund Publishing House Ltden_US
dc.relation.ispartofJournal of Pediatric Endocrinology and Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDoseen_US
dc.subjectGrowth hormoneen_US
dc.subjectGrowth hormone deficiencyen_US
dc.subjectIdiopathicen_US
dc.subjectPubertyen_US
dc.titleResponse to growth hormone with respect to pubertal status on increased dose in idiopathic growth hormone deficiency: An analysis of Turkish children in the KIGS database (Pfizer International Growth Study)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu